Your session is about to expire
← Back to Search
CAR T-cell Therapy
TIL Therapy for Cervical Cancer
Phase 2
Recruiting
Research Sponsored by Iovance Biotherapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
At least one resectable lesion (or aggregate of lesions resected) of a minimum 1.5 cm in diameter post-resection to generate TIL; surgical removal with minimal morbidity (defined as any procedure for which expected hospitalization is ≤ 3 days)
Neither chemoradiation, nor chemotherapy in the neoadjuvant or adjuvant settings are considered as a prior line of systemic therapy.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 60 months
Awards & highlights
Study Summary
This trial is testing a new cancer treatment that uses a patient's own immune cells to fight their cancer.
Who is the study for?
Adults over 18 with recurrent, metastatic, or persistent cervical cancer not treatable by surgery/radiation. Must have measurable lesions and be in good physical condition (ECOG 0-1). Previous systemic therapy is required; however, no more than three lines of chemotherapy for Cohorts 1 and 2. Participants must have adequate organ function, no active infections or HIV, and agree to contraception.Check my eligibility
What is being tested?
The trial studies LN-145 alone or combined with pembrolizumab in treating cervical carcinoma. It's a prospective study where patients receive TIL infusion after lymphodepletion. The goal is to evaluate the effectiveness of this adoptive cell therapy for those who've had previous treatments but still show disease progression.See study design
What are the potential side effects?
Potential side effects include reactions related to immune response due to TIL infusion such as inflammation in various organs, fatigue, blood disorders, infection risk increase from IL-2 treatment post-infusion and possible adverse reactions from pembrolizumab if used.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have a tumor that can be surgically removed and is at least 1.5 cm wide.
Select...
My previous treatments with chemotherapy or chemoradiation for cancer were not part of my ongoing systemic therapy.
Select...
My cervical cancer cannot be cured with surgery or radiation.
Select...
My cervical cancer has worsened after 1-3 chemotherapy treatments.
Select...
I stopped all cancer treatments 28 days before my tumor surgery.
Select...
I am fully active or can carry out light work.
Select...
My cancer has grown after my last treatment, confirmed by scans.
Select...
I have been treated with drugs like PD-1 or PD-L1 for my recurring or spreading cancer.
Select...
I've only had chemoradiation or surgery for my cancer, no other treatments.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 60 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 60 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Cohort 3: Adverse Events
Cohort 4: Efficacy and Adverse Events
Cohort 5: Efficacy and Adverse Events
Secondary outcome measures
Cohort 1 and 2: Adverse Events
Cohort 1 and 2: Disease Control Rate
Cohort 1 and 2: Duration of Response
+8 moreSide effects data
From 2022 Phase 2 trial • 64 Patients • NCT0308387371%
Thrombocytopenia [4]
71%
Chills
59%
Pyrexia
41%
Anaemia
35%
Leukopenia [1]
35%
Hypotension
35%
Hypophosphataemia
29%
Hypoalbuminaemia
29%
Hyponatraemia
29%
Neutropenia [3]
29%
Lymphopenia [2]
29%
Hypocalcaemia
24%
Nausea
24%
Diarrhoea
24%
Febrile neutropenia
24%
Dyspnoea
24%
Hypokalaemia
18%
Hypoxia
18%
Blood bilirubin increased
18%
Tachycardia
18%
Fatigue
18%
Hypertension
12%
Muscular weakness
12%
Procedural pain
12%
Constipation
12%
Stomatitis
12%
Sinus tachycardia
12%
Arthralgia
12%
Pain
12%
Hyperglycaemia
12%
Oedema peripheral
12%
Hypomagnesaemia
12%
Alopecia
12%
Wheezing
12%
Infusion related reaction
12%
Erythema
12%
Rash maculo-papular
12%
Flushing
12%
Productive cough
6%
Dysphagia
6%
Peripheral swelling
6%
Metabolic acidosis
6%
Mood altered
6%
Petechiae
6%
Pulmonary congestion
6%
Pruritus
6%
Haematuria
6%
Thrombophlebitis superficial
6%
Candida infection
6%
Blood alkaline phosphatase increased
6%
Abnormal dreams
6%
Headache
6%
Gastrooesophageal reflux disease
6%
Post procedural haemorrhage
6%
Rash erythematous
6%
Acute kidney injury
6%
Mass
6%
Activated partial thromboplastin time prolonged
6%
Blood lactate dehydrogenase increased
6%
Oropharyngeal pain
6%
Bronchitis
6%
Skin laceration
6%
Syncope
6%
Paraesthesia
6%
Restlessness
6%
Aspartate aminotransferase increased
6%
Abdominal distension
6%
Joint swelling
6%
Anxiety
6%
Dermatitis acneiform
6%
Vomiting
6%
Gastrostomy tube site complication
6%
Musculoskeletal chest pain
6%
Temperature intolerance
6%
Bronchitis viral
6%
Decreased appetite
6%
Acute respiratory distress syndrome
6%
Respiratory tract haemorrhage
6%
Pneumonia aspiration
6%
Insomnia
6%
Proteinuria
6%
Haemolytic anaemia
6%
Vision blurred
6%
Supraventricular tachycardia
6%
Neutropenia [1]
6%
Embolism
6%
Rash
6%
Odynophagia
6%
Cyanosis
6%
Hyperhidrosis
6%
Influenza
6%
Cough
6%
Back pain
6%
Acidosis
6%
Hypersomnia
6%
Pollakiuria
6%
Increased upper airway secretion
6%
Skin mass
6%
Deep vein thrombosis
6%
Bacteraemia
6%
Rhinorrhoea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cohort 2
Cohort 5
Cohort 1
Cohort 3
Cohort 4
Trial Design
5Treatment groups
Experimental Treatment
Group I: Cohort 5 Retreatment CohortExperimental Treatment1 Intervention
Patients who have been previously treated with LN-145 may be given a second treatment with TIL.
Group II: Cohort 4 - Non-enrolling CohortExperimental Treatment1 Intervention
Cohort includes patient population not meeting inclusion criteria in cohort 1 and 2. Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
Group III: Cohort 3 - Combination Arm (TIL + Pembrolizumab) - US OnlyExperimental Treatment1 Intervention
Patients will be administered with pembrolizumab, followed by NMA lymphodepletion, then infused with their autologous TIL (LN-145) followed by pembrolizumab every 3 or 6 weeks post IL-2 administration up to 24 months.
Group IV: Cohort 2 LN-145 monotherapyExperimental Treatment1 Intervention
Patients previously treated with an antiprogrammed cell death protein-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) checkpoint inhibitor: Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
Group V: Cohort 1 LN-145 monotherapyExperimental Treatment1 Intervention
Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LN-145
2017
Completed Phase 2
~70
Find a Location
Who is running the clinical trial?
Iovance Biotherapeutics, Inc.Lead Sponsor
20 Previous Clinical Trials
1,507 Total Patients Enrolled
Iovance Medical MonitorStudy DirectorIovance Biotherapeutics, Inc.
1 Previous Clinical Trials
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am receiving a specific chemotherapy regimen before my transplant.You have a condition that weakens your immune system, like severe combined immunodeficiency (SCID) or acquired immunodeficiency syndrome (AIDS).My heart's pumping ability is below normal, or I have moderate to severe heart problems.I have received bevacizumab and chemotherapy together before.I don't have severe side effects from previous treatments, except for nerve issues, hair loss, or skin color changes.I have not had an organ transplant or cell therapy, except for LN-145.I am under legal protection or unable to give consent myself.I have a tumor that can be surgically removed and is at least 1.5 cm wide.I do not have serious infections, bleeding disorders, or major heart, lung, or immune system illnesses.My previous treatments with chemotherapy or chemoradiation for cancer were not part of my ongoing systemic therapy.I haven't had any other cancers in the last 3 years, except for non-threatening skin or bladder cancer.I am unable to give consent due to an emergency situation.I have had immunotherapy for my condition before.I do not have any autoimmune or inflammatory disorders.I am fully active or can carry out light work.My cervical cancer has worsened after 1-3 chemotherapy treatments.My cervical cancer cannot be cured with surgery or radiation.I have received chemotherapy for recurrent or advanced cervical cancer.I stopped all cancer treatments 28 days before my tumor surgery.I don't have any ongoing infections and I am HIV negative.My cancer has grown after my last treatment, confirmed by scans.You have had a bad reaction or allergy to any part of the study drug LN-145 or other medications being used in the study.I am on hemodialysis for end-stage kidney disease.I have not had significant bleeding in the last 2 weeks.My organs are functioning well.I have been treated with drugs like PD-1 or PD-L1 for my recurring or spreading cancer.I've only had chemoradiation or surgery for my cancer, no other treatments.My brain metastases have been treated and stable for at least 14 days.I am 18 years or older.I need more than 10 mg/day of prednisone or an equivalent steroid.I have not received a live vaccine in the last 28 days.I have brain metastases that are either causing symptoms or have not been treated.
Research Study Groups:
This trial has the following groups:- Group 1: Cohort 1 LN-145 monotherapy
- Group 2: Cohort 5 Retreatment Cohort
- Group 3: Cohort 2 LN-145 monotherapy
- Group 4: Cohort 3 - Combination Arm (TIL + Pembrolizumab) - US Only
- Group 5: Cohort 4 - Non-enrolling Cohort
Awards:
This trial has 2 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What medical conditions does LN-145 typically address?
"LN-145 is an effective treatment option for malignant neoplasms, microsatellite instability high, and unresectable melanoma."
Answered by AI
What potential risks could be associated with administering LN-145 to patients?
"With prior data backing its safety, but limited evidence for efficacy, LN-145 was assigned a score of 2 out of 3."
Answered by AI
Is this research effort currently enrolling volunteers?
"Affirmative. The clinicaltrials.gov website attests that this medical experiment, first posted on June 22nd 2017, is presently looking for participants. Approximately 189 people need to be recruited from 19 different sites."
Answered by AI
Are there various sites in the city that are conducting this experiment?
"Eligible patients may be recruited to this clinical trial in three major sites, including University of Southern California Los Angeles (California), University of Chicago (Illinois) and University of California San Diego (Florida). Additionally, there are 19 other recruitment centres."
Answered by AI
What is the aim of this investigation?
"This clinical trial's primary goal is to gauge the efficacy and adverse events of LN-145 over a 60 month period. Secondary objectives include measuring disease control rate, overall survival, and side effects in patients with recurrent, metastatic or persistent cervical carcinoma as per RECIST v1.1 guidelines."
Answered by AI
What is the sample size of this research experiment?
"Iovance Biotherapeutics, Inc. has set a target of 189 participants for this trial; these individuals must meet the defined inclusion criteria in order to be eligible. This clinical study will take place at University of Southern California and University of Chicago, amongst other medical facilities."
Answered by AI
Have any preceding investigations explored the use of LN-145?
"LN-145 was initially analyzed in 2010 at the City of Hope. Presently, there are 250 studies that have been completed as well as 961 active trials taking place largely within Los Angeles County."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger